Healthcare / Drug Manufacturers - Specialty & GenericParis
$28.70
+0.60 (+2.14%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $27.5M · quality 81.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
68/100
B
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$498M
P/E
15.3x
↓EV/EBITDA
7.2x
↓ROE
8.3%
↑Gross Margin
73.0%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-2.1%
FCF CAGR
-9.5%
FCF margin
5.9%
FCF / Net income
0.91x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $501.1M · net income $32.6M · FCF $29.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $501.1M | $501.1M | $487.6M | $493.2M | $534.2M |
| Net Income | $32.6M | $32.6M | $11.3M | $35.8M | $44.7M |
| EBITDA | $62.6M | $62.6M | $58.2M | $73.7M | $77.0M |
| EPS | 1.88 | 1.88 | 0.65 | 2.06 | 2.57 |
| Gross Margin | 73.0% | 73.0% | 73.6% | 72.6% | 71.1% |
| Operating Margin | 7.3% | 7.3% | 7.3% | 8.3% | 10.6% |
| Net Margin | 6.5% | 6.5% | 2.3% | 7.3% | 8.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.04 | 0.03 | 0.04 |
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $29.7M | $29.7M | $23.6M | $27.5M | $40.1M |
| Returns | |||||
| ROE | 8.3% | 8.3% | 3.0% | 9.1% | 8.0% |
| Valuation | |||||
| P/E | 15.27 | 15.27 | 41.08 | 19.86 | 19.30 |
| EV/EBITDA | 7.20 | 7.20 | 7.11 | 8.83 | 8.23 |
| P/B | 1.27 | 1.27 | 1.23 | 1.80 | 1.55 |
| Growth & Yield | |||||
| Revenue Growth | 2.8% | 2.8% | -1.2% | -7.7% | — |
| EPS Growth | 189.2% | 189.2% | -68.4% | -19.8% | — |
| Dividend Yield | 4.8% | 4.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
10.6%
EPS terminal req.
$2.55
Spread vs growth
178.6%
5Y implied EPS CAGR
10.4%
EPS terminal req.
$3.08
Spread vs growth
178.8%
10Y implied EPS CAGR
10.2%
EPS terminal req.
$4.96
Spread vs growth
179.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+29.6%
Start / end P/E
35.4x → 15.3x
EPS bridge
0.65 → 1.88
Residual
-107.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.